Comparison of the Effect of Propacetamol, Ibuprofen or Their Combination on Postoperative Pain and Quality of Recovery After Laparoscopic Hernia Repair in Children

There are difficulties in the progress of the study and cancel the plan. The purpose of this study is to evaluate the postoperative pain control using non - opioidal analgesics in children. The investigators will investigate the effect of single use and combination of caldorol(ibuprofen) compare to denogan(propacetamol) in children.
Participants who receive the laparoscopic inguinal hernia repair between 6 months and 6 years old are divided 3 groups(caldolor, denogan, combination). Each groups are received a medication by protocol during surgery. After operation patient's pain score and use of additional analgesics are recorded in postanesthesia care unit and general ward.

开始日期2017-12-15

申办/合作机构

Yonsei University

NCT02577068 / CompletedN/AIIT

Combination Effect of Nefopam With Propacetamol for Postoperative Pain After Thyroidectomy

Patients undergoing thyroidectomy are suffering not only surgical wound pain but posterior neck pain because of neck extension position during the surgery. However, there has been little attention of posterior neck pain. Nefopam and Propacetamol have different pharmacodynamics and been used for postoperative pain control in thyroidectomy patients. The aim of this study is evaluation of combination effect of Nefopam and Propacetamol for acute wound pain, posterior neck pain and chronic pain after thyroidectomy.

开始日期2015-11-15

申办/合作机构

Yonsei University

100 项与盐酸丙帕他莫相关的临床结果

登录后查看更多信息

100 项与盐酸丙帕他莫相关的转化医学

登录后查看更多信息

100 项与盐酸丙帕他莫相关的专利（医药）

登录后查看更多信息

192

项与盐酸丙帕他莫相关的文献（医药）

2024-11-01·Heliyon

Efficacy of continuous preperitoneal ropivacaine infusion in women with cesarean section: A prospective, randomized controlled, single blinded study

Article

作者: Kim, Yeon-Hee ; Cho, Eui-Jin ; Lee, Hee Joung ; Jung, Gyul ; Kim, Woo Jeng ; Kim, Jong Bun ; Kim, Yoonho ; Hwang, In Seon

Background:

Adequate postoperative pain management after cesarean section is important for the prognosis of both mother and infant. However, excessive prescription of opioid analgesics has become a concern. This study evaluated the efficacy of local continuous subfascial infusion of ropivacaine in relieving postoperative pain and reducing opioid requirements in postpartum women with cesarean section.

Methods:

Seventy eligible women undergoing cesarean section were randomly allocated to the ropivacaine and the normal saline group for continuous subfascial wound infiltration. All patients received additional fentanyl through an intravenous patient-controlled analgesia pump. Pain score using the visual analog scale, opioid consumption through pump, and requirements for other analgesics were postoperatively measured within 8 h, 1 day, and 2 days after surgery. Statistical analysis was performed with independent t-tests for continuous variables and Chi-square tests for categorical variables. Paired Wilcoxon and student's t-tests were used for paired samples.

Results:

Sixty-nine patients (35 in the study and 34 in the control group) were analyzed. The mean VAS scores were lower in the study group all three periods, with significance achieved at day 2 (2.74 ± 0.95 versus 3.41 ± 1.33, p = 0.028). The intravenous fentanyl consumptions were significantly lower in the study group at all three periods. Total administration of additional non-opioid analgesics including ketorolac, propacetamol, and pethidine was higher in the control group.

Conclusions:

Continuous subfascial ropivacaine infusion is effective in relieving pain and reducing opioid-based analgesia and other analgesics requirements.

2024-01-01·Digital health

Predicting delirium and the effects of medications in hospitalized COVID-19 patients using machine learning: A retrospective study within the Korean Multidisciplinary Cohort for Delirium Prevention (KoMCoDe)

Article

作者: Park, Hye Yoon ; Lee, So Hee ; Park, Hye Youn ; Choe, Pyoeng Gyun ; Hur, Hyun Jung ; Hong, Arum ; Ro, Du Hyun ; Kim, Back ; Kim, Sung Nyun ; Ahn, Jang Ho

Objective:

Delirium is commonly reported from the inpatients with Coronavirus disease 2019 (COVID-19) infection. As delirium is closely associated with adverse clinical outcomes, prediction and prevention of delirium is critical. We developed a machine learning (ML) model to predict delirium in hospitalized patients with COVID-19 and to identify modifiable factors to prevent delirium.

Methods:

The data set (n = 878) from four medical centers was constructed. Total of 78 predictors were included such as demographic characteristics, vital signs, laboratory results and medication, and the primary outcome was delirium occurrence during hospitalization. For analysis, the extreme gradient boosting (XGBoost) algorithm was applied, and the most influential factors were selected by recursive feature elimination. Among the indicators of performance for ML model, the area under the curve of the receiver operating characteristic (AUROC) curve was selected as the evaluation metric.

Results:

Regarding the performance of developed delirium prediction model, the accuracy, precision, recall, F1 score, and the AUROC were calculated (0.944, 0.581, 0.421, 0.485, 0.873, respectively). The influential factors of delirium in this model included were mechanical ventilation, medication (antipsychotics, sedatives, ambroxol, piperacillin/tazobactam, acetaminophen, ceftriaxone, and propacetamol), and sodium ion concentration (all p < 0.05).

Conclusions:

We developed and internally validated an ML model to predict delirium in COVID-19 inpatients. The model identified modifiable factors associated with the development of delirium and could be clinically useful for the prediction and prevention of delirium in COVID-19 inpatients.

2022-06-01·Neurocritical care3区 · 医学

Risk Factors for Intravenous Propacetamol-Induced Blood Pressure Drop in the Neurointensive Care Unit: A Retrospective Observational Study

3区 · 医学

Article

作者: Lee, Eunah ; Jeon, Sujeong ; Lee, Junghwa ; Lee, Eunsook ; Lee, Euni ; Lee, Ju-Yeun ; Song, Young Joo ; Han, Moon-Ku ; Jeong, Han-Gil

BACKGROUND:

Intravenous propacetamol is commonly used to control fever and pain in neurocritically ill patients in whom oral administration is often difficult. However, several studies reported that intravenous propacetamol may cause blood pressure drop. Thus, we aimed to investigate the occurrence and risk factors for intravenous propacetamol-induced blood pressure drop in neurocritically ill patients.

METHODS:

This retrospective study included consecutive patients who were administered intravenous propacetamol in a neurointensive care unit at a single tertiary academic hospital between April 2013 and June 2020. The exact timing of intravenous propacetamol administration was collected from a database of the electronic barcode medication administration system. Blood pressure drop was defined as a systolic blood pressure below 90 mm Hg or a decrease by 30 mm Hg or more. Blood pressure, pulse rate, and body temperature were collected at baseline and within 2 h after intravenous propacetamol administration. The incidence of blood pressure drop was evaluated, and multivariable logistic regression analysis was performed to identify risk factors for blood pressure drop events.

RESULTS:

A total of 16,586 instances of intravenous propacetamol administration in 4916 patients were eligible for this study. Intravenous propacetamol resulted in a significant decrease in systolic blood pressure (baseline 131.1 ± 17.8 mm Hg; within 1 h 124.6 ± 17.3 mm Hg; between 1 and 2 h 123.4 ± 17.4 mm Hg; P < 0.01). The incidence of blood pressure drop events was 13.5% within 2 h after intravenous propacetamol. Older age, lower or higher baseline systolic blood pressure, fever, higher Acute Physiology and Chronic Health Evaluation II score, and concomitant administration of vasopressors/inotropes or analgesics/sedatives were significant factors associated with the occurrence of blood pressure drop events after intravenous propacetamol administration.

CONCLUSIONS:

Intravenous propacetamol can induce hemodynamic changes and blood pressure drop events in neurocritically ill patients. This study identified the risk factors for blood pressure drop events. On the basis of our results, judicious use of intravenous propacetamol is warranted for neurocritically ill patients with risk factors that make them more susceptible to hemodynamic changes.

项与盐酸丙帕他莫相关的新闻（医药）

2024-07-23

·米内网

第十批集采25个品种备战！千亿市场人福封王，海思科大涨103%，石药、华海蓄势待发

精彩内容在系列政策加持下，神经系统化药千亿市场跌宕起伏，集团及产品排名持续洗牌。目前190个神经系统药已有企业过评/视同过评，人福、华海领跑过评榜；48个品种（以通用名计）已纳入国采，25个品种备战第十批集采，石药、华海、扬子江等企业均有多个品种在列。千亿市场人福封王，海思科大涨103% 近年来，受国采、重点监控、医保目录调整等医改政策影响，神经系统化药院内市场风起云涌。米内网数据显示，2023年中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端神经系统化药（不含生物药）市场规模接近1000亿元，同比有小幅增长。近年来中国公立医疗机构终端神经系统化药销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局从集采属性看，非集采品种为神经系统化药销售“主力”，已集采品种的销售额逐年下滑，由2019年的超过390亿元减少至2023年的不足260亿元；从医保属性看，医保品种占主导地位，且近年来销售额逐年提升，非医保品种的销售额由2016年的超430亿元持续下滑至2023年的不足170亿元。在TOP20集团中，人福医药、扬子江药业、石药控股、恒瑞医药、恩华药业位列前五，其中人福医药首次“封王”，排位较2022年提升2个位次；从销售额增幅看，7家企业同比增长均达两位数，其中海思科大涨约103%，并首次跻身TOP20集团。 2023年中国公立医疗机构终端神经系统化药TOP5集团来源：米内网中国公立医疗机构药品终端竞争格局 “药王”再下跌！TOP20洗牌，4款注射剂亮了 2023年神经系统化药TOP20产品中，地佐辛注射液蝉联榜首，但销售额继2022年下滑约7%后，2023年再度下滑约23%；丁苯酞氯化钠注射液、注射用盐酸瑞芬太尼分别位列第二、第三，其中注射用盐酸瑞芬太尼涨超28%，排位较2022年提升1个位次。 2023年中国公立医疗机构终端神经系统化药TOP20产品来源：米内网综合数据库从销售额增速看，7个品种增幅达两位数，其中氢溴酸加兰他敏注射液、盐酸纳布啡注射液、咪达唑仑注射液、注射用盐酸丙帕他莫4款注射剂首次跻身TOP20产品，增幅分别达到168.5%、45.16%、28.29%、13.67%。 TOP20产品中，丙泊酚乳状注射液、草酸艾司西酞普兰片、奥氮平片、盐酸右美托咪定注射液、富马酸喹硫平片均已被纳入国采。 4+7及扩围集采品种奥氮平片2019年在中国公立医疗机构终端的销售额超过40亿元，在神经系统化药产品排名中排位第二，集采执行后2020年下滑约46%，2023年其销售额不足18亿元；盐酸右美托咪定注射液为4+7及扩围集采中唯一一个独家中选的产品，2021年在中国公立医疗机构终端的销售额突破40亿元，此后受续约降价影响，2022、2023年分别下滑38.05%、42.54%，2023年其销售额不足16亿元。近年来中国公立医疗机构终端奥氮平片、盐酸右美托咪定注射液销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局超100亿市场！25个品种备战第十批集采米内网数据显示，截至7月22日，有190个神经系统化药已有企业过评或视同过评。33个品种竞争激烈，过评企业数达10家及以上，其中有2个达30个以上，分别为对乙酰氨基酚片（32）、盐酸利多卡因注射液（31）。从企业过评情况看，人福医药、华海药业、恩华药业、上海医药、复星医药、扬子江药业、齐鲁制药7家药企（以集团计）已过评的神经系统药物品种数达20个及以上，其中人福医药、华海药业以27个品种领跑。已过评神经系统药品种数达20个及以上的集团在国家开展的七批八轮化药集采中，神经系统化药分别有6个、2个、10个、8个、3个、8个、3个、8个品种被纳入其中，合计48个品种（不含落标品种）。第十批集采如箭在弦。除去已纳入国家集采的品种，目前神经系统化药还有25个品种满足集采门槛，符合申报资格企业数达5家及以上。暂未纳入国采且符合5家及以上的神经系统化药注：销售额低于1亿元用*代表来源：米内网综合数据库 25个通用名药品2023年在中国公立医疗机构终端的销售额合计超过100亿元，其中吸入用七氟烷超30亿元，新斯的明注射剂超10亿元，坦度螺酮口服常释剂型，帕利哌酮缓释控释剂型超8亿元。从竞争情况看，拉考沙胺注射剂、伏硫西汀口服常释剂型、普瑞巴林口服液体剂、美金刚口服液体剂4个品种竞争激烈，符合申报资格企业数达10家及以上；曲马多注射剂、氟伏沙明口服常释剂型、奥卡西平口服常释剂型等10个品种竞争格局良好，目前符合申报资格企业数达5家。从过评企业看，石药控股以5个过评品种领跑，华海药业、扬子江药业、江西科睿药业、上海医药、华润医药均有4个过评品种在列，成都倍特药业、翰森制药、人福医药、石家庄四药均有3个过评品种在列，福安药业、天士力医药、四环医药等10余家企业均有2个过评品种在列。资料来源：米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至7月22日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

带量采购核酸药物

2024-07-20

·蒲公英Ouryao

40个品种！重点监控、超“黄线”监管名单公布 !

转自：上海阳光医药采购网编辑：水晶 7月18日，上海市医药集中招标采购事务管理所发布《关于公布2024年5月份药品挂网公开议价采购监管品种名单的通知》，公布2024年5月份挂网公开议价超“黄线”、未通过公允性评估、重点监控药品幅度靠前且有一定采购金额的品种各10个。《通知》也指出，公布品种仅作为提醒，部分品种确因成本上涨或有质量疗效优势等原因，涨幅议价；但也有部分品种价格明显高于同类在用品种。新申请超“黄线”品种合计10个：促肝细胞生长素注射液、注射用氯化钾、注射用酚磺乙胺、川芎茶调丸、奥扎格雷钠注射液、注射用天麻素、消炎利胆胶囊、冠心苏合软胶囊、丹参口服液等。原在库超“黄线”品种合计10个：注射用氢化可的松琥珀酸钠、氯化钠注射液、替米沙坦氢氯噻嗪胶囊、替米沙坦氢氯噻嗪片、注射用头孢唑肟钠、达肝素钠注射液、盐酸阿莫罗芬乳膏、复方氨基酸注射液(18AA-Ⅶ)等。未通过公允性品种合计10个：涉及注射用胶原酶、麻仁丸、冠心苏合软胶囊、保妇康凝胶、心悦胶囊、注射用盐酸丙帕他莫、蛤蚧定喘丸、参苓白术散、乳酶生片、生脉饮。 10个重点监控品种：小儿豉翘清热颗粒、利肺片、肌苷注射液、注射用盐酸罂粟碱、环磷腺苷注射液、注射用二羟丙茶碱、注射用氨苄西林钠、复方醋酸钠林格注射液、盐酸雷尼替丁注射液。

带量采购

2024-07-03

·药闻康策

10个品种列入重点监控！

☝ 点击上方一键预约 ☝ 最新最热的医药健康新闻政策 6 月 28 日，上海市医药集中招标采购事务管理所发布通知，公布了今年 4 月份挂网公开议价未通过公允性评估、重点监控药品幅度靠前且有一定采购金额的品种。从名单来看，“未通过公允性品种”和“重点监控品种”各有 10 个品种被列入。来看下哪些企业哪些品种进入了名单：重点监控品种（按采购药品金额降序排列） #通用名生产企业1小儿豉翘清热颗粒济川药业集团2利肺片重庆天致药业3肌苷注射液海南制药厂制药二厂4注射用氨苄西林钠四川制药制剂5注射用盐酸罂粟碱山东北大高科华泰制药6注射用二羟丙茶碱吉林津升制药7注射用头孢唑肟钠成都倍特药业8环磷腺苷注射液三才石岐制药9苏黄止咳胶囊扬子江药业集团北京海燕药业10利肺片三普药业未通过公允性品种（按超提示价幅度降序排列） #通用名生产企业1肌氨肽苷注射液北京赛升药业2注射用胶原酶辽宁味邦生物制药3冠心苏合软胶囊天津市中央药业4保妇康凝胶江西杏林白马药业5心悦胶囊吉林省集安益盛药业6注射用盐酸丙帕他莫贵州润生制药7参苓白术散河北扁鹊制药8生脉饮商丘市金马药业9麻仁丸华阳（恩施）药业10生脉饮商丘市金马药业据上海市药事所通知，公布该名单是根据《关于促进同通用名同厂牌药品省际间价格公平诚信、透明均衡的通知》（医保办函〔2023〕104号）、《药械重点监控监管工作规范》以及上海市全面议价挂网相关文件的要求，上海市进一步加强药品挂网公开议价采购的监管工作。上海市药事所这个举措，可以看作是今年初“四同药品”价格专项治理工作的延续。 “四同药品”，即通用名、剂型、规格、厂家均相同的药品。今年 1 月 5 日，国家医保局公布《关于促进同通用名同厂牌药品省际间价格公平诚信透明均衡的通知》（医保办函 [2023]104号），指导医药采购机构聚焦“四同药品”，推进价格专项治理工作。按照要求，常规挂网药品价格应回归至挂网监测价或以下。 (来源:医药代表）药闻康策新媒体矩阵微信公众号点击下方一键关注【免责声明】 1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。欢迎转发分享、点赞、点在看

带量采购一致性评价高管变更

100 项与盐酸丙帕他莫相关的药物交易

登录后查看更多信息